-transparent.png){kind=logo}
The LHRH analog Buserelin was used to treat 27 children (21 girls, 6 boys) with central precocious puberty. Nineteen patients had idiopathic precocious puberty and 8 had organic lesions (hamartoma, hydrocephalus or suprasellar arachnoid cyst). All patients received 20 or 30 micrograms/kg/day s.c. of Buserelin, and we obtained plasma E2 less than 20 pg/ml, vaginal maturation index less than 30 in girls or plasma testosterone less than 0.3 ng/ml in boys. The mean growth rate decreased from 9.3 +/- 0.5 to 4.6 +/- 1.3 cm/year after 3 years. The velocity of skeletal maturation decreased so that the final height prediction improved by a mean value of 1.6 SD. As the follow-up increases, this study confirms that LHRHa therapy is effective and potentially improves the final height of children presenting active and severe central precocious puberty.
R Rappaport, and
M Fontoura, and
R Brauner
April 1987,
Archives francaises de pediatrie,
R Rappaport, and
M Fontoura, and
R Brauner
May 1987,
European journal of pediatrics,
R Rappaport, and
M Fontoura, and
R Brauner
January 1989,
Journal of endocrinological investigation,
R Rappaport, and
M Fontoura, and
R Brauner
June 1985,
Clinical endocrinology,
R Rappaport, and
M Fontoura, and
R Brauner
March 1992,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
R Rappaport, and
M Fontoura, and
R Brauner
May 1993,
Annals of the New York Academy of Sciences,
R Rappaport, and
M Fontoura, and
R Brauner
November 1987,
European journal of pediatrics,
R Rappaport, and
M Fontoura, and
R Brauner
January 1988,
Gynakologische Rundschau,
R Rappaport, and
M Fontoura, and
R Brauner
December 1988,
Nihon Sanka Fujinka Gakkai zasshi,
R Rappaport, and
M Fontoura, and
R Brauner
April 1992,
Archives francaises de pediatrie,
